4.7 Article

Genetic Modifiers of Liver Disease in Cystic Fibrosis

期刊

JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
卷 302, 期 10, 页码 1076-1083

出版社

AMER MEDICAL ASSOC
DOI: 10.1001/jama.2009.1295

关键词

-

资金

  1. Cystic Fibrosis Foundation [SILVER0Z00, KNOWLE00A0, DRUMM04P0, DRUMM0A00]
  2. National Institutes of Health [NIH R01GM074175, NIH/NIDDK DK066368, CTRC RR00046, CTSA UL1RR025747]
  3. Prince Charles Hospital Foundation
  4. OWHC/CIHR Fellowship
  5. Czech Ministry of Health [VZFNM00064203, NS9488/3]
  6. MIUR, Rome, Italy
  7. Regione Campania, Italy
  8. Health Research Board Grant [RFRD-05-07]
  9. Genome Canada through the Ontario Genomics Institute [2004-OGI-3-05]
  10. Lloyd Carr-Harris Foundation
  11. Canadian Cystic Fibrosis Foundation

向作者/读者索取更多资源

Context A subset (approximate to 3%-5%) of patients with cystic fibrosis (CF) develops severe liver disease with portal hypertension. Objective To assess whether any of 9 polymorphisms in 5 candidate genes (alpha(1)-antitrypsin or alpha(1)-antiprotease [SERPINA1], angiotensin-converting enzyme [ACE], glutathione S-transferase [GSTP1], mannose-binding lectin 2 [MBL2], and transforming growth factor beta 1 [TGFB1]) are associated with severe liver disease in patients with CF. Design, Setting, and Participants Two-stage case-control study enrolling patients with CF and severe liver disease with portal hypertension (CFLD) from 63 CF centers in the United States as well as 32 in Canada and 18 outside of North America, with the University of North Carolina at Chapel Hill as the coordinating site. In the initial study, 124 patients with CFLD (enrolled January 1999-December 2004) and 843 control patients without CFLD were studied by genotyping 9 polymorphisms in 5 genes previously studied as modifiers of liver disease in CF. In the second stage, the SERPINA1 Z allele and TGFB1 codon 10 genotype were tested in an additional 136 patients with CFLD (enrolled January 2005-February 2007) and 1088 with no CFLD. Main Outcome Measures Differences in distribution of genotypes in patients with CFLD vs patients without CFLD. Results The initial study showed CFLD to be associated with the SERPINA1 Z allele (odds ratio [OR], 4.72; 95% confidence interval [CI], 2.31-9.61; P = 3.3 x 10(-6)) and with TGFB1 codon 10 CC genotype (OR, 1.53; 95% CI, 1.16-2.03; P = 2.8 x 10(-3)). In the replication study, CFLD was associated with the SERPINA1 Z allele (OR, 3.42; 95% CI, 1.54-7.59; P = 1.4 x 10(-3)) but not with TGFB1 codon 10. A combined analysis of the initial and replication studies by logistic regression showed CFLD to be associated with SERPINA1 Z allele (OR, 5.04; 95% CI, 2.88-8.83; P = 1.5 x 10(-8)). Conclusions The SERPINA1 Z allele is a risk factor for liver disease in CF. Patients who carry the Z allele are at greater risk (OR, approximate to 5) of developing severe liver disease with portal hypertension. JAMA. 2009;302(10):1076-1083

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.7
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

Article Gastroenterology & Hepatology

Effects of prolonged proton pump inhibitor treatment on nutritional status and respiratory infection risk in cystic fibrosis: A matched cohort study

Laura Zazzeron, Gianfranco Alicandro, Valeria Dacco, Chiara Lanfranchi, Anna Bulfamante, Calogero Sathya Sciarrabba, Fabiola Corti, Carla Colombo

Summary: This study found that the use of proton pump inhibitors (PPI) as adjuvant therapy in people with cystic fibrosis (pwCF) may increase the risk of respiratory infection and does not improve nutritional status.

DIGESTIVE AND LIVER DISEASE (2023)

Article Respiratory System

Beyond borders: cystic fibrosis survival between Australia, Canada, France and New Zealand

Adele Coriati, Xiayi Ma, Jenna Sykes, Sanja Stanojevic, Rasa Ruseckaite, Lydie Lemonnier, Clemence Dehillotte, Jan Tate, Catherine Ann Byrnes, Scott C. Bell, Pierre Regis Burgel, Anne L. Stephenson

Summary: This study compared the survival rates of cystic fibrosis patients in countries with single-payer healthcare systems, taking into account markers of disease severity. The results showed that France had significantly higher survival rates compared to other countries, despite having a higher proportion of underweight patients.

THORAX (2023)

Article Endocrinology & Metabolism

Hypocalcemia During Lenvatinib Treatment for Advanced Thyroid Cancer: Clinical Features and Management in a Real-Life Setting

Simone De Leo, Matteo Trevisan, Carla Colombo, Claudia Moneta, Noemi Giancola, Laura Fugazzola

Summary: This retrospective cohort study aimed to investigate the incidence, characteristics, and management of hypocalcemia in patients with advanced thyroid cancer treated with lenvatinib. The study found a higher incidence of hypocalcemia (24%) compared to the registration trial (6.9%). The hypocalcemia in this cohort was caused by both PTH-dependent and PTH-independent mechanisms.

THYROID (2023)

Article Respiratory System

Characterization of CFTR mutations in people with cystic fibrosis and severe liver disease who are not eligible for CFTR modulators

Carla Colombo, Grant A. Ramm, Anders Lindblad, Fabiola Corti, Luigi Porcaro, Federico Alghisi, Irina Asherova, Helen Evans, Nataliya Kashirskaya, Elena Kondratyeva, Peter J. Lewindon, Isabelle de Monestrol, Mark Oliver, Chee Y. Ooi, Rita Padoan, Sahana Shankar, Gianfranco Alicandro

Summary: Cystic-fibrosis-related liver disease (CFLD) is a variable phenotype of CF. CFTR modulator therapies, elexacaftor, tezacaftor, and ivacaftor (ETI), and ivacaftor (IVA), are available for CF patients. Genetic eligibility evaluation showed that 13% of patients without CFLD and 11% of patients with severe CFLD are not eligible for ETI or IVA therapy. Ineligible patients cannot benefit from these new treatments.

JOURNAL OF CYSTIC FIBROSIS (2023)

Review Genetics & Heredity

iPSC-derived organ-on-a-chip models for personalized human genetics and pharmacogenomics studies

Victoria E. J. M. Palasantzas, Isabel Tamargo-Rubio, Kieu Le, Jelle Slager, Cisca Wijmenga, Iris H. Jonkers, Vinod Kumar, Jingyuan Fu, Sebo Withoff

Summary: Genome-wide association studies (GWAS) have identified numerous genetic variants associated with complex genetic diseases and drug efficacy. However, functional characterization of these variants is challenging due to the lack of human model systems. Organ-on-a-chip (OoC) platforms, enabled by advances in molecular and nanotechnology, provide personalized platforms for studying the impact of genetics and environment on organ physiology. This review highlights the technology and showcases the potential of OoCs in disease modeling and pharmacogenetic research.

TRENDS IN GENETICS (2023)

Article Microbiology

Glutamine Metabolism Supports the Functional Activity of Immune Cells against Aspergillus fumigatus

Daniela Antunes, Samuel M. Goncalves, Vasiliki Matzaraki, Claudia S. Rodrigues, Relber A. Goncales, Joana Rocha, Jorge Saiz, Antonio Marques, Egidio Torrado, Ricardo Silvestre, Fernando Rodrigues, Frank L. van de Veerdonk, Coral Barbas, Mihai G. Netea, Vinod Kumar, Cristina Cunha, Agostinho Carvalho

Summary: The fungal pathogen Aspergillus fumigatus can cause severe infections in immunocompromised patients. Cellular metabolism plays a crucial role in the immune response to this pathogen. This study highlights the importance of glutamine metabolism in macrophage activation and defense against A. fumigatus. Glutamine metabolism is essential for phagocytosis and cytokine production, and genetic variation in glutamine metabolism genes affects the response to fungal stimulation.

MICROBIOLOGY SPECTRUM (2023)

Article Endocrinology & Metabolism

Endocrine-related adverse conditions induced by tyrosine kinase inhibitors

Simone De Leo, Matteo Trevisan, Claudia Moneta, Carla Colombo

Summary: Tyrosine kinase inhibitors (TKIs) have shown improved outcomes for various tumors, but they can also cause adverse events and endocrine-related toxicities. The most common endocrinopathies caused by TKIs are thyroid dysfunction and hypothyroidism, with potential mechanisms including dysfunction of the thyroid gland and hormone metabolism impairment. TKIs can also affect other glands, leading to adrenal insufficiency, growth retardation, hypogonadism, and fertility impairment. TKIs can also disrupt bone metabolism and cause metabolic alterations, such as hypoglycemia and hyperglycemia. These endocrine-related adverse events should be managed by endocrinologists with replacement therapy or symptomatic treatment.

ANNALES D ENDOCRINOLOGIE (2023)

Article Immunology

Evaluation of Acebilustat, a Selective Inhibitor of Leukotriene B4 Biosynthesis, for Treatment of Outpatients With Mild-Moderate Coronavirus Disease 2019 (COVID-19): A Randomized, Double-Blind, Placebo-Controlled Phase 2 Trial

Joseph E. Levitt, Haley Hedlin, Sophie Duong, Di Lu, Justin Lee, Bryan Bunning, Nadia Elkarra, Benjamin A. Pinsky, Eileen Heffernan, Eric Springman, Richard B. Moss, Hector F. Bonilla, Julie Parsonnet, Roham T. Zamanian, Jamison J. Langguth, Jenna Bollyky, Chaitan Khosla, Mark R. Nicolls, Manisha Desai, Angela J. Rogers

Summary: The study aimed to evaluate the effectiveness of Acebilustat in treating outpatients with COVID-19, and the results showed that the medication did not shorten symptom duration.

CLINICAL INFECTIOUS DISEASES (2023)

Article Biochemistry & Molecular Biology

Counteracting the Common Shwachman-Diamond Syndrome-Causing SBDS c.258+2T>C Mutation by RNA Therapeutics and Base/Prime Editing

Laura Peretto, Elena Tonetto, Iva Maestri, Valentino Bezzerri, Roberto Valli, Marco Cipolli, Mirko Pinotti, Dario Balestra

Summary: Shwachman-Diamond syndrome (SDS) is a common inherited bone marrow failure syndrome caused by SBDS gene mutations. The mutation in the SBDS c.258+2T>C variant affects splicing, but some correct transcripts can still be produced, explaining the survival of SDS patients. Correction approaches at the RNA and DNA levels, such as engineered U1snRNA, trans-splicing, and base/prime editors, can partially counteract the mutation effect and lead to correctly spliced transcripts. DNA editors, in particular, may offer a potential innovative therapy for SDS by reverting the mutation and potentially selecting bone-marrow cells.

INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2023)

Review Pediatrics

Cepacia syndrome in cystic fibrosis: A systematic review of the literature and possible new perspectives in treatment

Valeria Dacco, Gianfranco Alicandro, Alessandra Consales, Chiara Rosazza, Calogero S. Sciarrabba, Lisa Cariani, Carla Colombo

Summary: This study provides insights into Cepacia syndrome (CS), a rare but potentially lethal complication of Burkholderia cepacia complex (BCC) infection in cystic fibrosis (CF) patients. The study includes a systematic review of 18 cases of CS reported over the last 24 years, with a high mortality rate of 50%. The data are insufficient to determine the most effective therapeutic approach for CS.

PEDIATRIC PULMONOLOGY (2023)

Article Health Care Sciences & Services

Association of Oxygen Therapy with the Natural Disease Progression of Cystic Fibrosis: A Multi-State Model of the European Cystic Fibrosis Society Patient Registry

Simone Gambazza, Annalisa Orenti, Giovanna Pizzamiglio, Anna Zolin, Carla Colombo, Dario Laquintana, Federico Ambrogi, ECFSPR

Summary: This study aimed to understand the prognosis for people with cystic fibrosis (pwCF) on oxygen therapy (OT), evaluating the probability of lung transplantation (LTx) and death in pwCF with and without OT. The study found that OT is strongly associated with poor survival in pwCF, highlighting the importance of harmonizing CF care throughout European countries and minimizing the onset of pulmonary gas exchange abnormalities.

THERAPEUTICS AND CLINICAL RISK MANAGEMENT (2023)

Article Immunology

Integration of Candida albicans-induced single-cell gene expression data and secretory protein concentrations reveal genetic regulators of inflammation

Collins K. Boahen, Roy Oelen, Kieu Le, Mihai G. Netea, Lude Franke, Monique G. P. van der Wijst, Vinod Kumar

Summary: Both gene expression and protein concentrations are regulated by genetic variants. Exploring the regulation of eQTLs and pQTLs simultaneously in a context- and cell-type dependent manner may help unravel the mechanistic basis for genetic regulation of pQTLs. By conducting meta-analysis of Candida albicans-induced pQTLs from two population-based cohorts and intersecting the results with Candida-induced cell-type specific expression association data (eQTL), we found systematic differences between pQTLs and eQTLs, indicating the limitation of using eQTLs as a proxy for pQTLs. Additionally, our study identified SNPs affecting protein networks and implicated specific genomic loci through colocalization of pQTLs and eQTLs signals.

FRONTIERS IN IMMUNOLOGY (2023)

Review Endocrinology & Metabolism

Polycystic ovary syndrome and thyroid disorder: a comprehensive narrative review of the literature

Stefano Palomba, Carla Colombo, Andrea Busnelli, Donatella Caserta, Giovanni Vitale

Summary: This study comprehensively reviews the relationship between polycystic ovary syndrome (PCOS) and thyroid dysfunction by analyzing available evidence in nine main areas of interest. The results suggest that PCOS and thyroid disorders are closely related, and their coexistence may increase the reproductive and metabolic risk of patients. Regular screening for thyroid function and thyroid-specific autoantibodies in women with PCOS, particularly before and during pregnancy, is highly recommended.

FRONTIERS IN ENDOCRINOLOGY (2023)

Article Respiratory System

Lung Function Decline in Cystic Fibrosis Impact of Data Availability and Modeling Strategies on Clinical Interpretations

Rhonda Szczesniak, Eleni-Rosalina Andrinopoulou, Weiji Su, Pedro M. Afonso, Pierre-Regis Burgel, Elizabeth Cromwell, Emrah Gecili, Enas Ghulam, Christopher H. Goss, Nicole Mayer-Hamblett, Ruth H. Keogh, Theodore G. Liou, Bruce Marshall, Wayne J. Morgan, Joshua S. Ostrenga, David J. Pasta, Sanja Stanojevic, Claire Wainwright, Grace C. Zhou, Gabriela Fernandez, Aliza K. Fink, Michael S. Schechter

Summary: The study aims to estimate the rate of lung function decline in cystic fibrosis and examine the impact of different research methods on the results. The findings show that the choice of modeling strategy can affect the estimated rate of decline, but the results are generally reliable under specific scenarios.

ANNALS OF THE AMERICAN THORACIC SOCIETY (2023)

暂无数据